A Hardware Implementation Method of Multi-Objective Genetic Algorithms

CEC2006 : IEEE International Conference on Evolutionary Computation , Jul 16-21, 2006 , Vancouver, BC, CanadaMulti-objective genetic algorithms (MOGAs) are approximation techniques to solve multi-objective optimization problems. Since MOGAs search a wide variety of pareto optimal solutions at the same time, MOGAs require large computation power. In order to solve practical sizes of the multi objective optimization problems, it is desirable to design and develop a hardware implementation method for MOGAs with high search efficiency and calculation speed. In this paper, we propose a new method to easily implement MOGAs as high performance hardware circuits. In the proposed method, we adopt simple Minimal Generation Gap (MGG) model as the generation model, because it is easy to be pipelined. In order to preserve diversity of individuals, we need a special selection mechanism such as the niching method which takes large computation time to repeatedly compare superiority among all individuals in the population. In the proposed method, we developed a new selection mechanism which greatly reduces the number of comparisons among individuals, keeping diversity of individuals. Our method also includes a parallel execution architecture based on Island GA which is scalable to the number of concurrent pipelines and effective to keep diversity of individuals. We applied our method to multi-objective Knapsack Problem. As a result, we confirmed that our method has higher search efficiency than existing method

Flexible implementation of genetic algorithms on FPGAs

FPGA '06 : ACM/SIGDA 14th international symposium on Field programmable gate arrays , Feb 22-24, 2006 , Monterey, CA, USAGenetic algorithms (GAs) are useful since they can find near optimal solutions for combinatorial optimization problems quickly. Although there are many mobile/home applications of GAs such as navigation systems, QoS routing and video encoding systems, it was difficult to apply GAs to those applications due to low computational power of mobile/home appliances. In this paper, we propose a technique to flexibly implement genetic algorithms for various problems on FPGAs. For the purpose, we propose a basic architecture which consists of several modules for GA operations to compose a GA pipeline, and a parallel architecture consisting of multiple concurrent pipelines. The proposed architectures are simple enough to be implemented on FPGAs, applicable to various problems, and easy to estimate the size of the resulting circuit. We also propose a model for predicting the size of resulting circuit from given parameters consisting of the problem size, the number of concurrent pipelines and the number of candidate solutions for GA. Based on the proposed method, we have implemented a tool to facilitate GA circuit design and development. This tool allows designers to find appropriate parameter values so that the resulting circuit can be accommodated in the target FPGA device, and to automatically obtain RTL VHDL description. Through experiments using Knapsack Problem and TSP, we show that the FPGA circuits synthesized based on the proposed method run much faster and consume much lower power than software implementation on a PC and that our model can predict the size of the resulting circuit accurately enough

General Architecture for Hardware Implementation of Genetic Algorithm

FCCM 2006 : 14th Annual IEEE Symposium on Field-Programmable Custom Computing Machines , Apr 24-26, 2006 , Napa, CA, USAIn this paper, the authors propose a technique to flexibly implement genetic algorithms (GAs) for various problems on FPGAs. For the purpose, the authors propose a common architecture for GA. The proposed architecture allows designers to easily implement a GA as a hardware circuit consisting of parallel pipelines which execute GA operations. The proposed architecture is scalable to increase the number of parallel pipelines. The architecture is applicable to various problems and allows designers to estimate the size of resulting circuits. The authors give a model for predicting the size of resulting circuits from given parameters. Based on the proposed method, the authors have implemented a tool to facilitate GA circuit design and development. Through experiments using knapsack problem and traveling salesman problem (TSP), the authors show that the FPGA circuits synthesized based on the proposed method run much faster and consume much lower power than software implementation on a PC and the model can predict the size of the resulting circuit accurately enough

Diagnosis and Prognostication of Ductal Adenocarcinomas of the Pancreas Based on Genome-Wide DNA Methylation Profiling by Bacterial Artificial Chromosome Array-Based Methylated CpG Island Amplification

To establish diagnostic criteria for ductal adenocarcinomas of the pancreas (PCs), bacterial artificial chromosome (BAC) array-based methylated CpG island amplification was performed using 139 tissue samples. Twelve BAC clones, for which DNA methylation status was able to discriminate cancerous tissue (T) from noncancerous pancreatic tissue in the learning cohort with a specificity of 100%, were identified. Using criteria that combined the 12 BAC clones, T-samples were diagnosed as cancers with 100% sensitivity and specificity in both the learning and validation cohorts. DNA methylation status on 11 of the BAC clones, which was able to discriminate patients showing early relapse from those with no relapse in the learning cohort with 100% specificity, was correlated with the recurrence-free and overall survival rates in the validation cohort and was an independent prognostic factor by multivariate analysis. Genome-wide DNA methylation profiling may provide optimal diagnostic markers and prognostic indicators for patients with PCs

Current state of therapeutic development for rare cancers in Japan, and proposals for improvement

This article discusses current obstacles to the rapid development of safe and effective treatments for rare cancers, and considers measures required to overcome these challenges. In order to develop novel clinical options for rare cancers, which tend to remain left out of novel therapeutic development because of their paucity, efficient recruitment of eligible patients, who tend to be widely dispersed across the country and treated at different centers, is necessary. For this purpose, it is important to establish rare cancer registries that are linked with clinical studies, to organize a central pathological diagnosis system and biobanks for rare cancers, and to consolidate patients with rare cancers to facilities that can conduct clinical studies meeting international standards. Establishing an all‐Japan cooperative network is essential. Clinical studies of rare cancers have considerable limitations in study design and sample size as a result of paucity of eligible patients and, as a result, the level of confirmation of the efficacy and safety shown by the studies is relatively low. Therefore, measures to alleviate these weaknesses inherent to external conditions need to be explored. It is also important to reform the current research environment in order to develop world‐leading treatment for rare cancers, including promotion of basic research, collaboration between industry and academia, and improvement of the infrastructure for clinical studies. Collaboration among a wide range of stakeholders is required to promote the clinical development of treatment for rare cancers under a nationwide consensus

Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure:Rationale for and design of the EMPA-AHF trial

Aims: The aim of the EMPA-AHF trial is to clarify whether early initiation of a sodium-glucose co-transporter 2 inhibitor before clinical stabilization is safe and beneficial for patients with acute heart failure (AHF) who are at a high risk of adverse events. Methods: The EMPA-AHF trial is a randomized, double-blind, placebo-controlled, multicentre trial examining the efficacy and safety of early initiation of empagliflozin (10 mg once daily). In total, 500 patients admitted for AHF will be randomized 1:1 to either empagliflozin 10 mg daily or placebo at 47 sites in Japan. Study entry requires hospitalization for AHF with dyspnoea, signs of volume overload, elevated natriuretic peptide, and at least one of the following criteria: estimated glomerular filtration rate &lt;60 mL/min/1.73 m2; already taking ≥40 mg of furosemide daily before hospitalization; and urine output of &lt;300 mL within 2 hours after an adequate dose of intravenous furosemide. Patients will be randomized within 12 hours of hospital presentation, with treatment continued up to 90 days. The primary outcome is the clinical benefit of empagliflozin on the win ratio for a hierarchical composite endpoint consisting of death within 90 days, heart failure rehospitalization within 90 days, worsening heart failure during hospitalization, and urine output within 48 hours after treatment initiation. Conclusion: The EMPA-AHF trial is the first to evaluate the efficacy and safety of early initiation of empagliflozin in patients with AHF considered to be at high risk under conventional treatment.</p

Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure:Rationale for and design of the EMPA-AHF trial

Aims: The aim of the EMPA-AHF trial is to clarify whether early initiation of a sodium-glucose co-transporter 2 inhibitor before clinical stabilization is safe and beneficial for patients with acute heart failure (AHF) who are at a high risk of adverse events. Methods: The EMPA-AHF trial is a randomized, double-blind, placebo-controlled, multicentre trial examining the efficacy and safety of early initiation of empagliflozin (10 mg once daily). In total, 500 patients admitted for AHF will be randomized 1:1 to either empagliflozin 10 mg daily or placebo at 47 sites in Japan. Study entry requires hospitalization for AHF with dyspnoea, signs of volume overload, elevated natriuretic peptide, and at least one of the following criteria: estimated glomerular filtration rate &lt;60 mL/min/1.73 m2; already taking ≥40 mg of furosemide daily before hospitalization; and urine output of &lt;300 mL within 2 hours after an adequate dose of intravenous furosemide. Patients will be randomized within 12 hours of hospital presentation, with treatment continued up to 90 days. The primary outcome is the clinical benefit of empagliflozin on the win ratio for a hierarchical composite endpoint consisting of death within 90 days, heart failure rehospitalization within 90 days, worsening heart failure during hospitalization, and urine output within 48 hours after treatment initiation. Conclusion: The EMPA-AHF trial is the first to evaluate the efficacy and safety of early initiation of empagliflozin in patients with AHF considered to be at high risk under conventional treatment.</p